Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM AMINOSALICYLATE vs CAPREOMYCIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.
Tuberculosis (second-line therapy, in combination with other antituberculous agents)
Treatment of pulmonary tuberculosis as part of combination therapy,Salvage therapy for multidrug-resistant tuberculosis
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Hepatic acetylation (N-acetyltransferase) and renal excretion of metabolites.
Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration.
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
50-60% bound to albumin; binding is saturable at high concentrations.
Approximately 30% bound to serum proteins (albumin).
0.2-0.3 L/kg (distributes into total body water; low tissue penetration except inflamed pleural fluid and caseous granulomas).
0.4-0.6 L/kg (suggests distribution primarily into extracellular fluid; poor CNS penetration unless meninges inflamed).
Oral: 90-100% (rapidly absorbed from GI tract); no parenteral formulation available.
IM: 100% (only IM route available; no oral formulation).
For GFR <30 m L/min: reduce dose to 4 g orally twice daily (total 8 g/day). For GFR <10 m L/min: administer 4 g orally once daily. No adjustment for GFR ≥30 m L/min.
Cr Cl 50-80 m L/min: 15 mg/kg every 24-36 hours; Cr Cl 30-50 m L/min: 15 mg/kg every 48 hours; Cr Cl 10-30 m L/min: 15 mg/kg every 72 hours; Cr Cl <10 m L/min: 15 mg/kg every 96-120 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: consider 50% dose reduction. Child-Pugh Class C: use with caution; consider further reduction or alternative therapy as pharmacokinetics are not well studied.
No dose adjustment required for hepatic impairment; monitor for hepatotoxicity.
Children: 150-300 mg/kg/day orally divided into 3-4 doses, not to exceed 12 g/day. Intravenous: 150-200 mg/kg/day as a continuous infusion or in divided doses.
15-30 mg/kg intramuscularly or intravenously once daily (maximum 1 g) for 60 days, then 15-30 mg/kg 2-3 times weekly (maximum 1 g).
Start at lower end of dosing range (e.g., 4 g orally twice daily) due to age-related decline in renal function. Monitor renal function and adjust per GFR-based guidelines. Caution with hepatic impairment.
Initiate at lower end of dosing range; adjust based on renal function due to age-related decline in glomerular filtration rate.
None.
None officially listed by FDA; however, use with caution due to potential nephrotoxicity and ototoxicity.
May cause hepatotoxicity, hypersensitivity reactions (fever, rash, eosinophilia), gastrointestinal intolerance, and crystalluria. Monitor liver function tests and renal function periodically.
Nephrotoxicity: Monitor renal function; risk increases with cumulative dose and concomitant nephrotoxic drugs.,Ototoxicity: Can cause vestibular and cochlear damage, especially in patients with renal impairment.,Neuromuscular blockade: May exacerbate weakness in patients with myasthenia gravis or other neuromuscular disorders.,Electrolyte disturbances: Hypokalemia, hypocalcemia, and hypomagnesemia due to renal tubular effects.
Hypersensitivity to aminosalicylic acid or any component; severe renal impairment (Cr Cl < 10 m L/min).
Hypersensitivity to capreomycin or any component,Pre-existing severe renal impairment (Cr Cl < 30 m L/min) unless benefit outweighs risk,Pre-existing hearing loss
Take with or after meals to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of hepatotoxicity and GI upset. No specific food interactions; but a low-fat diet may help reduce GI side effects.
No specific food interactions. However, maintain adequate hydration and electrolyte-rich diet (bananas, potatoes) to mitigate hypokalemia.
FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and third trimesters: No specific known fetal risks; however, theoretical risk of kernicterus due to bilirubin displacement from albumin binding, though not confirmed with aminosalicylic acid.
Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxicity and nephrotoxicity to fetus.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants (e.g., hypersensitivity, gastrointestinal disturbance), decision should be made to discontinue nursing or the drug, taking into account importance of drug to mother.
Small amounts excreted in breast milk; not expected to cause adverse effects in infants due to poor oral absorption. M/P ratio unknown.
No established dose adjustment guidelines for pregnancy; pharmacokinetic changes (increased volume of distribution, increased renal clearance) may theoretically reduce serum concentrations; therapeutic drug monitoring is not routinely recommended but may be considered if efficacy is in question.
No dose adjustment recommended for pregnancy alone; however, concurrent use may require monitoring and adjustment. No pharmacokinetic changes reported.
Sodium aminosalicylate (PAS) is a bacteriostatic agent used in combination therapy for multidrug-resistant tuberculosis. Administer with or after meals to reduce gastrointestinal upset. Monitor liver function tests and renal function periodically. Watch for hypersensitivity reactions, including fever, rash, and eosinophilia. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolytic anemia.
Capreomycin is a second-line injectable agent for multidrug-resistant tuberculosis (MDR-TB). Monitor for nephrotoxicity (creatinine, BUN) and ototoxicity (audiometry, vestibular testing). Electrolyte disturbances (hypokalemia, hypomagnesemia) are common; replace aggressively. Administer deep IM injection; rotate sites. Contraindicated in pregnancy (teratogenic). Synergistic with other antituberculars; never use as monotherapy.
Take this medication with or after food to reduce stomach upset.,Do not skip doses or stop taking this medication without consulting your doctor.,Report any signs of allergic reaction such as rash, fever, or swelling.,Avoid alcohol while taking this medication.,Keep all appointments for blood tests to monitor liver and kidney function.,Contact your doctor if you experience nausea, vomiting, abdominal pain, or yellowing of skin or eyes.
Take exactly as prescribed; do not skip doses to prevent resistance.,Report hearing loss, ringing in ears, or dizziness immediately.,Report decreased urine output, swelling, or unusual fatigue.,You will need regular blood tests (kidney function, electrolyte levels).,Avoid alcohol and excessive salt intake.,Contact your doctor if you develop severe injection site pain or fever.
No interactions on record
"Decamethonium, a depolarizing neuromuscular blocker, and capreomycin, an aminoglycoside antibiotic, synergistically prolong neuromuscular blockade. Capreomycin decreases acetylcholine release at the motor endplate, while decamethonium persistently depolarizes the postsynaptic membrane, leading to enhanced and prolonged muscle relaxation. This interaction can result in extended respiratory depression and apnea, particularly during anesthesia or in critically ill patients."
"Streptozocin, a nitrosourea alkylating agent, may potentiate the neuromuscular blocking effects of capreomycin, a cyclic polypeptide antibiotic that inhibits neuromuscular transmission by reducing acetylcholine release at the motor endplate. This interaction can lead to prolonged or enhanced muscle weakness, including respiratory depression, particularly in patients with underlying neuromuscular disorders (e.g., myasthenia gravis) or those receiving other neuromuscular blocking agents. The clinical outcome may range from mild skeletal muscle weakness to severe respiratory compromise requiring mechanical ventilation."
"Paromomycin, an aminoglycoside antibiotic, and capreomycin, a polypeptide antibiotic, both possess neuromuscular blocking properties. Their co-administration can result in additive or synergistic neuromuscular blockade, potentially leading to prolonged or enhanced muscle relaxation, respiratory depression, or apnea. This interaction is particularly dangerous in patients receiving general anesthetics, neuromuscular blocking agents, or those with underlying neuromuscular disorders such as myasthenia gravis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM AMINOSALICYLATE vs CAPREOMYCIN SULFATE, answered by our medical review team.
SODIUM AMINOSALICYLATE is a Antitubercular Agent that works by Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.. CAPREOMYCIN SULFATE is a Antitubercular Agent that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM AMINOSALICYLATE and CAPREOMYCIN SULFATE depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM AMINOSALICYLATE is: 4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.. The standard adult dose of CAPREOMYCIN SULFATE is: 15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM AMINOSALICYLATE and CAPREOMYCIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM AMINOSALICYLATE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and th. CAPREOMYCIN SULFATE is classified as Category C. Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.